Esperion Therapeutics (ESPR) Other Non Operating Income (2012 - 2026)

Esperion Therapeutics has reported Other Non Operating Income for 15 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 10.35% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$1.2 million (up 97.64% YoY), and the FY2024 full-year result was -$54.9 million, down 1137.95% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $1.2 million, up from -$2.4 million in the prior quarter.
• The five-year high for Other Non Operating Income was $5.3 million in Q4 2023, with the low at -$53.2 million in Q2 2024.
• Historically, Other Non Operating Income has averaged -$2.6 million across 5 years, with a median of $1.2 million in 2026.
• Annual changes were most pronounced in 2022 — Other Non Operating Income surged 4969.23% — and 2024, when it tumbled 3304.82%.
• Esperion Therapeutics' Other Non Operating Income stood at $1.4 million in 2022, then jumped by 290.48% to $5.3 million in 2023, then sank by 132.47% to -$1.7 million in 2024, then plunged by 40.57% to -$2.4 million in 2025, then soared by 148.99% to $1.2 million in 2026.
• The last three Other Non Operating Income figures came in at $1.2 million (Q1 2026), -$2.4 million (Q4 2025), and $1.1 million (Q1 2025), per Business Quant data.